New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer

Tony Berberabe, MPH @OncBiz_Wiz
Published: Thursday, Jul 04, 2019
Michael Birrer,

Michael Birrer, MD, PhD
The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced, according to Michael J. Birrer, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication